Belfast – October 14, 2026 -- Cumulus Neuroscience and Transpharmation Ltd. have formed a strategic partnership to align EEG and behavioral endpoints from preclinical models through first-in-human trials, targeting a therapeutic area where an estimated 6.7% of candidates progress from nonclinical development to FDA approval (Sertkaya et al., JAMA Netw Open, 2024).
Partners target the measurement break between animal studies and Phase 1
The two companies will jointly advise biopharma sponsors preparing for first-in-human studies. They will recommend which EEG paradigms to run preclinically based on how the same measures will be captured in the clinic. Each company will no longer scope its portion of a programme in isolation.
The partners argue the endpoint typically switches at the point a programme becomes most expensive. Preclinical work relies on controlled behavioral and electrophysiological data. Clinical work moves to subjective symptom scales and questionnaires, administered infrequently in heterogeneous populations. When an early study fails, sponsors often cannot tell whether the mechanism, exposure, endpoint or population was at fault.
Transpharmation brings 26 benchmarked endpoints; Cumulus brings an FDA-cleared headset
Transpharmation contributes a sleep EEG and quantitative EEG platform spanning rodent and canine models, with 26 endpoints benchmarked against clinical gold standards. Its expertise is rooted in its founders' work on orexin and sleep pharmacology at GSK.
Cumulus supplies the NeuLogiq Platform, developed with 10 of the world's leading pharma companies. It pairs an FDA 510(k)-cleared, self-applicable wireless dry-EEG headset with tablet-based gamified assessments for clinic and home use.
Ketamine analysis showed a conserved EEG signature across four species
In February 2026, Transpharmation's John Huxter and Cumulus's Florentine Barbey co-presented a cross-species analysis at the 6th Annual Psychedelic Therapeutics & Drug Development Conference in New Orleans. In Transpharmation's mouse, rat and dog datasets, ketamine produced a dose-dependent EEG fingerprint. Spectral power fell in the approximately 10 Hz theta-sigma band and rose in the 50-100 Hz high-gamma band. The effects tracked an approximately one-hour pharmacokinetic window.
A Cumulus double-blind crossover study in 30 healthy adult male volunteers compared a sub-anaesthetic infusion of racemic ketamine (0.5 mg/kg) with saline. It found increased high-frequency power in the same direction. Dry EEG captured data before, during and after infusion and again at 24 hours, and paired blood sampling allowed direct PK/PD linkage.
A separate Transpharmation psilocybin dataset showed selective REM sleep suppression over four hours, matching the time course of plasma psilocin. The partners describe this as a physiological readout of 5-HT2A target engagement rather than an inference from peripheral exposure.
Executives frame the offer as an earlier design conversation
Transpharmation CEO Mark Duxon said the partnership lets the CRO design a preclinical EEG and behavioral package knowing how endpoints will be captured in the clinic. He said that discussion should happen before a Phase 1 protocol is finalised, not after the data are in.
Cumulus CEO Tina Sampath said the alignment gives developers "a continuous, objective line of evidence that does not break at the species boundary."
The partners say continuity only delivers value if clinical measurement can be deployed at scale. NeuLogiq is designed for non-expert clinic staff and patients. It enables structured in-clinic sampling and high-frequency longitudinal sampling at home without the site burden that would make neurophysiological assessment impractical. Sponsors with assets approaching IND-enabling work or first-in-human design can request a joint scoping discussion with either company.